Rheumatoid Arthritis Clinical Trial
Official title:
99mTc-labelled D-Glucosamine in the Evaluation of Disease Activity in Patients With Degenerative and Inflammatory Rheumatic Conditions
Preliminary data following a pilot study from our institution confirms the ability of
99mTc-glucosamine (99mTc-ECDG) to differentiate between active, subclinical and quiescent
disease in patients with rheumatoid arthritis, scleroderma lung, and vasculitis. We propose
to extend these findings and further evaluate this imaging modality for its clinical
utility, limitations, and application.
An unacceptably high level of morbidity exists amongst patients suffering from rheumatic
disease. This is often the result of mild disease being missed or misdiagnosed, and therapy
inordinately delayed or inappropriate. The currently used therapeutic agents themselves have
associated side-effects adding to unfavourable clinical outcomes. There is therefore a need
for a superior, less expensive and more easily accessible imaging modality to assess the
degree of inflammation to guide the clinician. Glucosamine is absorbed and metabolised in a
manner not too dissimilar to that of glucose, and it can be readily labelled to form
99mTc-ECDG. Scans can be acquired within 3 hours of intravenous administration of this
agent, accurately depicting sites of active inflammation/disease.
HYPOTHESIS Glucose is a vital cellular substrate that accumulates at inflamed tissues
because of the greater metabolic needs of the cells during active disease. Glucosamine,
being an analogue of glucose, is metabolised more quickly in inflamed than non-inflamed
tissue and thus 99mTc-ECDG scintigraphy like 18-Fluorodeoxyglucose (18FDG-PET) scintigraphy
allows for detection of active inflammation. Unlike current bone scans this agent has the
sensitivity to detect subclinical inflammatory disease that would in turn provide essential
information to ensure accurate diagnosis and treatment.
Aim 1. To evaluate the role of 99mTc-ECDG in Rheumatoid Arthritis (RA). Both as a monitoring
and diagnostic tool.
Approach. Three separate cohorts of patients suffering from RA will be recruited;
1. Patients with newly diagnosed RA;
2. Patients with active and long-standing RA before and after treatment with anti-TNF;
3. Patients with RA in remission with or without anti-TNF treatment.
5-10 patients will be recruited into each cohort. In order to provide written consent all
patients will be older than 18 years old. Exclusion criteria will include any patient with
an allergy to glucosamine or seafood, any patient with end-stage renal or hepatic disease,
pregnancy or lactation. No restrictions will be imposed on the treatment patients are able
to receive for their underlying rheumatic condition, nor for any other medical condition
while in this study. Patients will be required to cease any glucosamine therapy for three
days prior to the injection of the radiotracer.
An evaluation of patient's history and physical examination will be conducted prior to
tracer administration. All relevant disease will be documented as well as concurrent
illnesses and treatment regimes. A rheumatologist will assess disease severity and
documented as per recommendations outlined under the PBS guidelines for subsidised treatment
(HIC - Medicare Australia). Biological markers of disease will be acquired from each patient
at the time of clinical assessment, including ESR, CRP levels, rheumatoid factor and
anti-citrullinated peptide antibodies. Similar assessments will be undertaken at six monthly
intervals for three years. These results will be used to correlate with the scan findings.
Patients from cohort A & B will have their initial scans acquired prior to the commencement
of therapy. Scans will be repeated six months later in all patients. Results will be
analysed on both a per patient basis and a per joint basis.
AIM 1a. To correlate 99mTc-ECDG joint uptake with clinical parameters of disease.
The scan findings of each group will be graded by a nuclear medicine physician (SA) noting
the pattern of tracer uptake and the intensity of tracer uptake. Relative tracer activity in
joints will be correlated with the activity in the brain / skull (where essentially no
uptake is evident). In addition, the neighbouring muscle tissue, the liver and the cardiac
blood pool activity at the two scanning time points (15 and 120 minutes) will be evaluated.
A four point (0-3) grading system will be utilised to semi-quantify the scan findings, and
is as follows:
0 - Nil uptake - defined as no increased / minimally increased tracer activity in region of
interest (ROI; activity approximates uptake in the brain);
1. - Mild - tracer uptake in ROI approximates that of the neighbouring muscle tissue;
2. - Moderate - tracer uptake in ROI is greater than that in the vicinity of the heart;
and,
3. - Severe - tracer uptake in ROI approximates that of the liver. The scan findings will
then be compared to clinical parameters as documented at the time of the study and on
follow-up assessment (as outlined under aim 1). This will enable the investigators to
assess disease progression or remission over time. It will thus be possible to evaluate
the predictive nature of the scan findings in this respect.
AIM 1b. To evaluate 99mTc-ECDG joint uptake differences before and after treatment. That is,
to predict response to therapy. One of the purposes of follow-up is to identify changes in
disease activity over time. The clinical and scan findings at the time of recruitment will
be compared to the corresponding findings from the follow-up assessments (as outlined in Aim
1 & 1a). Patients from cohorts A & B will permit assessment of clinical response to therapy.
Thus, any regression of disease activity or otherwise, can be correlated with the
differences as depicted on the scans acquired at baseline and at six months later. In cohort
B, the 99mTc-ECDG scans acquired at baseline and 6 months later from inadequate responders
to conventional therapy will be compared to those with a favourable clinical response.
Follow-up studies in patients from cohort C (disease in remission) will provide information
regarding:
- the reproducibility of the scan findings in patients who remain clinically stable,
- the significance of probable subclinical disease (increased tracer uptake in joints of
patients who are otherwise asymptomatic on the baseline study and the changes observed
on the follow-up scans),
- and the sensitivity in detecting recurrent disease (changes in tracer distribution in
joints that become inflamed in the intervening period).
AIM 1c. To correlate between findings on 99mTc-ECDG with other imaging modalities, including
bone scintigraphy and 18FDG-PET scintigraphy. In at least 3 RA patients with a wide range of
disease activity, a bone scan will be performed within 72h of the 99mTc-ECDG. At least 3
patients will also undergo 18FDG-PET scintigraphy. These scans will be evaluated by an
experienced nuclear medicine physician (SA), and correlated to the patient profile and the
99mTc-ECDG scan findings. These cohorts will enable the value of the different clinical
information provided by each imaging technique and their complementary nature to be
evaluated. It is anticipated that this study will take 30 months to complete. All patients
will be recruited with the aim to recruit all patients in the first 12 months and followed
up for at least 24 months.
AIM 2. To investigate the role of 99mTc-ECDG in detecting seronegative spondyloarthritis.
Distinguishing back-pain related to disease flare-up/progression and alternative causes
(osteoarthritis, disc pathology) in patients with early AS is difficult. Therapy is
cause-specific. Inappropriate application of therapeutic regimes can delay recovery often
leading to unforeseen complications with poor outcomes (eg. steroid-related osteoporotic
vertebral crush fractures). Plain X-rays, CT scans and MRI will effectively highlight the
irreversible chronic changes of this disease. However, these techniques seldom detect the
earliest pathogenic changes, being the most amendable to therapeutic intervention.
99mTc-ECDG, by virtue of its ability to accumulate at sites of inflammation, appears
successful in identifying early and mild disease. Furthermore, the pattern of tracer
distribution will assist in differentiating between the competing diagnoses. A control group
of 10-15 patients with mechanical back pain will be used as controls 10-15 AS patients with
varying degrees of disease activity will be recruited. TNF-alpha inhibitor therapy will be
administered to patients meeting the necessary guidelines and scans performed pre and post
treatment. Repeat studies will be acquired 6 months later in all patients. A comparison of
clinical findings, documented by experienced Rheumatologists with regular six-monthly
follow-up over three years will be conducted. The predictive value of these scans with
respect to treatment response will also be assessed as outlined in Aim 1b. MRI scans, the
gold standard for sacro-ileitis, will be acquired within 72 hours of the 99mTc-ECDG scans,
for comparison of findings in the lumbo-sacral region. A number of these patients will also
undergo bone scintigraphy and / or 18FDG-PET scintigraphy (as outlined in Aim 1c), to
evaluate the comparative value of these alternate imaging modalities.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |